Edition:
India

Indivior PLC (INDV.L)

INDV.L on London Stock Exchange

387.70GBp
21 Feb 2018
Change (% chg)

7.20 (+1.89%)
Prev Close
380.50
Open
377.90
Day's High
387.70
Day's Low
377.90
Volume
563,261
Avg. Vol
2,522,264
52-wk High
436.60
52-wk Low
246.50

Select another date:

Thu, Feb 15 2018

Indivior bets on $1 billion anti-addiction shot as legal bill weighs

LONDON Britain's Indivior is launching a new weapon to fight the U.S. opioid crisis this month, but high hopes for its once-monthly injection were offset on Thursday by the need to set aside more cash for legal disputes.

UPDATE 2-Indivior bets on $1 bln anti-addiction shot as legal bill weighs

LONDON, Feb 15 Britain's Indivior is launching a new weapon to fight the U.S. opioid crisis this month, but high hopes for its once-monthly injection were offset on Thursday by the need to set aside more cash for legal disputes.

Indivior legal costs rise, new anti-addiction drug ready

LONDON, Feb 15 Britain's Indivior, which makes drugs to treat opioid addiction and plans to launch a key new product this month, said on Thursday it had increased provisions for investigative and antitrust litigation matters to $438 million.

BRIEF-Indivior Says FY 2017 ‍Net Revenue Increased 3% On Reported Basis

* FY 2017 ‍NET REVENUE AT $1,093M (FY 2016: $1,058M) INCREASED 3% ON A REPORTED BASIS (3% AT CONSTANT EXCHANGE)​

BRIEF-Indivior Asserts New Patent Against ANDA-Filers

* U.S. UNIT FILED PATENT LAWSUITS AGAINST DR. REDDY'S, ACTAVIS, PAR, ALVOGEN AND TEVA FOR INFRINGEMENT OF UNITED STATES PATENT NO. 9,855,221

BRIEF-Indivior Expects High Teens Effective Tax Rate For 2018​

* ‍EXPECTS ITS FUTURE US AFTER-TAX INCOME TO BE POSITIVELY IMPACTED BY RECENTLY-LEGISLATED CHANGES TO US CORPORATE TAXES​

UK's Indivior replaces $484 mln in dollar, euro debt facilities

Dec 19 British drugmaker Indivior said it replaced all of its U.S. dollar and euro denominated outstanding term loans of about $484 million.

BRIEF-‍Indivior Says Repricing And Maturity Extension Of Term Loan Facilities

* ‍INDIVIOR ANNOUNCES REPRICING AND MATURITY EXTENSION OF TERM LOAN FACILITIES AND REPLACEMENT OF CREDIT FACILITY​

BRIEF-Indivior Announces NDA Acceptance Of RBP-7000 Risperidone Monthly Depot

* INDIVIOR ANNOUNCES NDA ACCEPTANCE OF RBP-7000 RISPERIDONE MONTHLY DEPOT

U.S. FDA accepts application for Indivior's new schizophrenia drug

U.S. Food and Drug Administration (FDA) accepted Indivior's application for its new schizophrenia treatment, the British drugmaker said on Tuesday, boosting hopes of marketing the drug in the country.

Select another date: